市場調査レポート
商品コード
1297782
肺動脈性肺高血圧症の世界市場-2023年~2030年Global Pulmonary Arterial Hypertension Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
肺動脈性肺高血圧症の世界市場-2023年~2030年 |
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
肺動脈性肺高血圧症の世界市場規模は2022年に70億米ドルで、2023~2030年の市場推計・予測期間中にCAGR 5.3%で成長し、2030年には106億米ドルに達すると推定・予測されています。肺高血圧症は完治させることはできないが、薬物療法によって症状を軽減し、患者の管理を助けることができます。
肺高血圧症は時間とともに悪化することが多いです。治療せずに放置すると、心不全を引き起こし、死に至ることもあります。したがって、できるだけ早く治療を開始する必要があります。肺高血圧症が他の病気によって引き起こされている場合は、まずその基礎疾患に対処すべきです。そうすることで、肺動脈への永続的な損傷を避けることができます。
肺動脈性肺高血圧症市場の成長を促進する要因の1つは、老年人口における疾病率の増加です。例えば、最近の研究では、米国と欧州の統計によると、肺動脈性肺高血圧症は、他の心血管系疾患を併存していることが多い高齢者で発見されることが多くなっています。この研究では、肺動脈性肺高血圧症の診断時の年齢の中央値は60歳で、患者の29%が70歳以上であることが判明しました。
肺動脈性肺高血圧症の治療費が高いことは、肺動脈性肺高血圧症市場を停滞させる市場の阻害要因の一つです。研究によると、PAH患者は過剰な薬物使用のために多額の薬局経費を負担しています。
PAHの併用療法はかなり一般的で、PAH患者の46パーセントが二重療法、9パーセントが三重療法を受けており、支払者の負担を増加させる可能性がある2。二重療法と三重療法に関する重要な臨床試験であるTRITONでは、ベースラインに対する肺血管抵抗(PVR)の有意な減少が認められ、これまでの漸進的な治療法のエスカレーションを上回っている3,4。
COVID-19に伴う肺動脈性肺高血圧症の主な原因機序は、グループ3のPAHと同様に広範な肺障害(間質および肺胞の炎症による)と肺血管系の変化(血栓性/血栓塞栓性プロセスによって誘発される、第4群のPAHと同様、肺血管系の変化(血栓・血栓塞栓過程、内皮傷害、あるいは少なくとも低酸素性血管収縮による)であるが、場合によっては、人工呼吸で使用される呼気終末陽圧の影響も追加要因として考えられます。
The Global Pulmonary Arterial Hypertension Market size was worth US$ 7 billion in 2022 and is estimated to reach US$ 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2023-2030. Although pulmonary hypertension cannot be cured, medication may reduce symptoms and assist patients in managing the condition.
Pulmonary hypertension often worsens over time. If left untreated, it can lead to cardiac failure, which can be deadly. Thus, treatment should begin as soon as possible. If pulmonary hypertension is caused by another ailment, the underlying condition should be addressed first. This can occasionally avoid lasting damage to the pulmonary arteries.
Increased rate of disease in Geriatric patients is one the driver that increases the market growth of the pulmonary arterial hypertension market. For instance, a recent study found that statistics from the United States and Europe show that pulmonary arterial hypertension is increasingly being detected in older individuals, who commonly have other cardiovascular comorbidities. During the study, it was discovered that the median age at the time of diagnosis of pulmonary arterial hypertension was 60 years, and 29% of the patients were 70 years or older.
High cost of treatment of Pulmonary arterial hypertension is one of the markets hinder which stops the Pulmonary arterial hypertension market for instance, According to studies, individuals with PAH have large pharmacy expenses due to excessive medication use.1 To complicate matters, PAH is frequently treated using injected medications that might be billed under the medical benefit with minimal visibility to cost.
Combination therapy for PAH is fairly common: 46 percent of PAH patients are on dual therapy regimens, and 9 percent are on triple therapy regimens, potentially raising payor expenses.2 TRITON, a crucial trial on double and triple therapy, exhibited significant reductions in pulmonary vascular resistance (PVR) relative to baseline, outperforming previous progressive therapy escalation.3,4 These people are enjoying longer lives and avoiding the need for lung transplants.
Covid possesses the main responsible mechanisms for Pulmonary Arterial Hypertension associated with COVID-19 are considered extensive pulmonary damage (due to interstitial and alveolar inflammation) as in PAH of group 3 and alterations in pulmonary vasculature (induced by thrombotic/thromboembolic processes, endothelial injury, or, at the very least, hypoxic vasoconstriction) as in PAH of group 4, but in some cases, an additional factor could be the consequences of positive end-Ex expiratory pressure used in mechanical ventilation.
The market for next-generation contact lenses and visual prostheses is segmented by drug class, route of administration, and distribution channel on a global scale.
The Oral route segment, with a percentage of around 44.3%, is dominated by market players' products during the forecast period as it is the most prevalent form of drug administration. It is the preferred method because to its advantages, such as non-invasiveness, patient compliance, and convenience of medicine administration. Medication solubility, mucosal transparency, and the stability of the digestive system environment are all variables that impact oral medication absorption.
Because inhaled drugs specifically target the receptor, they can be supplied at a lower dose than systemic therapies (oral or injectable), resulting in less mild adverse effects. Regarding clinical efficacy, the three types of aerosol devices (MDI, DPI, and nebulizer) may be comparable. As a result, the market for inhalational administration is likely to be the fastest-growing sector.
North America is estimated to hold around 39.1% of the total market share throughout the forecast period in terms of revenue share. The sophisticated healthcare system in the region, which offers access to innovative therapies, is responsible for a large portion of this. Increased awareness, a high incidence of diagnosis, and favorable government policies contribute to market development.
In North America, pulmonary hypertension is normally diagnosed and managed by specialized healthcare experts such as pulmonologists, cardiologists, and PH specialists. They collaborate with patients to create personalized treatment programs that may include medicines, lifestyle changes, and, in certain situations, sophisticated treatments, including pulmonary arterial hypertension (PAH)-targeted pharmaceuticals, prostacyclin analogs, or lung transplantation.
The major global players include: Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation
The Global Pulmonary Arterial Hypertension Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.
LIST NOT EXHAUSTIVE